作者：安通陵 来源：原创 发布日期：08-26
A | 白糖：消息方面，据巴西对外贸易秘书处（Secex）出口数据，巴西8月前三周出口糖169.37万吨，日均出口量为11.29万吨，较上年8月全月日均出口量17.72万吨减少36%。 (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 
。
B | 现货报价方面，广西制糖集团报价区间为5170~5240元/吨，多家企业下调10元/吨；云南制糖集团报价为4990~5040元/吨，下调10元/吨；加工糖主流报价区间为5580~6050元/吨。原糖方面，自印度进口消息公布后，市场缺乏新的利好，上行乏力，后期关...。
Current article:http://4a2g.roubutianquegumaigoubingdian.cyou/scv6hos/20260826/1945.html
Published on:05:11:14